Integer Holdings Corporation reported a net income of $23.6 million and EPS of $0.69 for Q2 2026, exceeding revenue estimates despite ongoing merger-related operational constraints. The company entered into a definitive merger agreement with KKR affiliates under customary closing conditions, triggering strategic review efforts while limiting operational flexibility. Integer continues to focus on manufacturing excellence in medical device components, sustaining high quality control and long-term OEM contracts. Key risks include merger completion uncertainty, regulatory approval timelines, and supply chain dynamics affecting capacity utilization.